Close

Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness

Go back to Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness

Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan

October 6, 2016 7:39 AM EDT

Chardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid... More

Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'

October 6, 2016 7:23 AM EDT

Credit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.

Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the... More

Alnylam (ALNY) PT Cut to $58 at Jefferies

October 6, 2016 6:47 AM EDT

Jefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.

Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of... More

Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback

October 6, 2016 6:44 AM EDT

Jefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.

Amin commented, "ALNY... More

JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral

October 6, 2016 6:41 AM EDT

JPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $51.00 (from $83.00).

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.

... More

Barclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight

October 6, 2016 6:41 AM EDT

Barclays downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $50.00 (from $85.00).

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.

... More

Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform

October 6, 2016 6:39 AM EDT

Leerink Partners downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Market Perform with a price target of $40.00 (from $107.00) after the company discontinued development of revusiran.

Analyst Michael Schmidt commented, "We are downgrading ALNY to Market Perform following today's news that the company has discontinued development of... More

BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure

October 6, 2016 6:29 AM EDT

BMO Capital upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Market Perform to Outperform with a price target of $48.00 (from $42.00), saying the company could benefit from Alnylam (NASDAQ: ALNY) discontinuation of the Revusiran program fter observing an imbalance of... More

Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran

October 5, 2016 4:31 PM EDT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This... More